pyridoxine and Apoplexy

pyridoxine has been researched along with Apoplexy in 10 studies

4,5-bis(hydroxymethyl)-2-methylpyridin-3-ol: structure in first source
vitamin B6 : Any member of the group of pyridines that exhibit biological activity against vitamin B6 deficiency. Vitamin B6 deficiency is associated with microcytic anemia, electroencephalographic abnormalities, dermatitis with cheilosis (scaling on the lips and cracks at the corners of the mouth) and glossitis (swollen tongue), depression and confusion, and weakened immune function. Vitamin B6 consists of the vitamers pyridoxine, pyridoxal, and pyridoxamine and their respective 5'-phosphate esters (and includes their corresponding ionized and salt forms).

Research

Studies (10)

Authors

Clinical Trials (1)

Trial Overview

Trial Outcomes

EKG Categoryy Changes Related to Homocysteine Changes

Change in EKG ( normalize, unchanged, became abnormal) when homocysteine (Hcy) increased or decreased from week 16 on adalimumab to week 28 on adalimumab plus folic acid, vitamins B6 and B12 in adault psoriasis patients ages 18-65 with moderate to severe plaque psoriasis. (NCT01704599)
Timeframe: Week 16 to Week 28

Number of Participants in Categories or Increasing and Decreasing Changes Within the CBC (Complete Blood Count)

Change in CBC parameter: white blood count or hemoglobin or hematocrit ( as measured week 16 on adalimumab and at week 28 after 12 more weeks on adalimuamb , folic acid, B6 and B12) in adults ages 18-65 with moderate to severe plaque psoriasis. (NCT01704599)
Timeframe: Week 16 and Week 28

Number of Participants in the Categories of Having and Not Having an Adverse Event

"Worsening psoriasis or development or worsening of measured condition or new pathology not seen by week 16 but developed at weeks 28 or first discoved by telephone call day 70 post study:~AE Humira only" (NCT01704599)
Timeframe: After Week 16 of study

Number of Participants in the Categories of Having and of Not Having a Serious Adverse Event (SAE)

A serious adverse event is hosptalization or death or pathology leading to early termination of a participant from the study. This was to be reported at anytime during the 28 week study of adult patients ages 18-65 with moderate to severe plaque psoriasis though categorized by Week 16 (on adalimumab alone, by Week 28 (on adalimuamb plus 3 B vitaminsand by day 70 post Week 28. (NCT01704599)
Timeframe: By Week 16, by Week 28 and by Day 70 post Week 28.

Number of Participants in the Categories of Normalizing, Unchanging and Newly Abnormal Electrocardiograms (EKGs)

An electrocardiogram (EKG) is used to evaluate the electrical activity of the heart by converting this activity into line tracings on paper.. Electrodes (small, plastic patches) are placed at certain locations on the chest, arms, and legs. When the electrodes are connected to an EKG machine by lead wires, the electrical activity of the heart is measured, interpreted, and printed out for the doctor's information and further interpretation. This test was to be administered to adults age 18 or older with moderate to severe plaque psoriasis patients at week 0, 16 and week 28 of this study. (NCT01704599)
Timeframe: Week 16 and then Week 28 after another 12 weeks on Humira plus vitamins and if early termination

Number of Participants Who Fulfilled the Category of Having Height Measured

Height is the distance from the bottom (soles of feet ) to the top (top of head) of a person when that person is standing in this study using ruler in inches.Participants measured were adults age 18 or older with moderate to severe plaque psoriasis. (NCT01704599)
Timeframe: Week 0 at Start of Adalimumab

Number of Participants With a Categorical Change in Static Physician Global Assessment (sPGA):

Number of participants with a category change in Physician static Global Assessment (sPGA): 7 point score from 0 (clear) to 6 measuring amount of surface covered and plaque qualities: thickness & erythema plus scaling. Dynamic score compares baseline with either improvement/ worsening of the same factors measured in the sPGA using the 0-6 scoring range but focused on change. sPGA at weeks 16 AND 28. dynamic PGA to be categoically measured at.weeks16 and 28. (NCT01704599)
Timeframe: Week 16 and Week 28

Number of Participants With a Categorical DLQI (Dermatology Life Quality Index) Change

DLQI is 10 questions examining impact of skin disease on quality of life: (1) symptoms & feelings (2) daily activities (3) leisure (4) work & school (5) personal relationship (6) treatment. To be administered to adults over 18 years with moderate to severe plaque psoriasis at week 0 (no systemic psoriasis medication);. weeks 16 ( after 16 weeks of adalimumab) and week 28 (after 16 weeks adalimumab then 12 weeks of adalimumab plus daily 5 mg folic acid, 100 mg vitamin B6 and 1000 mcg B12). (NCT01704599)
Timeframe: Week 16 and Week 28

Number of Participants With Category Change in Serum Folic Acid Level.

Serum folic acid level in adults ages 18 and older with mild to moderate plaque psoriasis measured at week 16 after 16 weeks adalimumab and at week 28 after 16 weeks adalimumab plus 12 weeks of adalimumab and daily 5 mg folic acid, 100 mg vitamin B6 and 1000 mcg B12. (NCT01704599)
Timeframe: Weeks 16 and 28

Number of Participants With Category Change in Serum VEGF (Vascular Endothelial Growth Factorl)

Adult particpants ages 18 or older with moderate to severe plaque psoriasis were to have serum VEGF measured at week 0 on no systemic psoriasis medication then at both weeks 16 on adalimumab and at week 28 on adalimumab plus folic acid, B6 and Vitamin B12. Subjects raniked by BMI week 0 low to high (NCT01704599)
Timeframe: At Screening visit, Week 16 on Humira, after another 12 weeks on Humira plus vitamins and if early termination

Number of Participants With Category Change in Vitamin B12 Blood Level

Adult participants 18 years or older with moderate to severe plaque psoriasis were to have serum B12 levels measures Weeks 0 (on no systemic psoriasis medication), 16 (on adalimumab) and week 28 (on adalimumab plus daily 5 mg folic acid, 100 mg vitamin B6 and 1000 mcg B12. (NCT01704599)
Timeframe: At Week 16 and Week 28

Number of Participants Within Categories of Body Temperature Change

Using a thermometer for body temperature on degrees Fahrenheit. Participants to be measured were adults 18 years or older with moderate to severe plaque psoriasis with temperature to be measured at week 16 16 weeks of adalimumab and week 28 after 16 weeks of adalimumab then 12 weeks of adalimumab plus 5 mg folic acid, 100 mg vitamin B6 and 1000 mcg of B12. (NCT01704599)
Timeframe: Weeks 16 and 28

Number of Participants Within the Categories of Elevated and Normal Helicobacter Pylori Antibody

Adult participants age 18 years or older with moderate to severe plaque psoriasis with serum IgG antibodies against Helicobacter pylori bacteria using commercial ELISA assay during the 28 week study. (NCT01704599)
Timeframe: Week 28 after 16 weeks of Adalimumab then 12 of Adalimumab-Vitamins

Number of Participants Within the Categories of Increasign and Decreasing Body Weight

Weight is how heavy a participant is. Weight in pounds of each study adult participant age 18-65 years with moderate to severe plaque psoriasis measured at weeks 16 and compared to week 28 of study. (NCT01704599)
Timeframe: Week 16 and Week 28

Number of Participants Within the Categories of Increasing and Decreasing Blood Pressure and Pulse Measures:

Blood pressure is the force the heart exerts against the walls of arteries as it pumps the blood out to the body. The unit of measurement is millimeters of mercury (mm Hg). Pulse is the number of times your heart beats per minute. The unit of measurement is beats per minute (BPM). These test measurements compared in adults with moderate to severe plaque psoriasis week 16 after 16 weeks adalimumab and week 28 after 16 weeks adalimumab plus 5 mg folic acid, 100 mg vitamin B6 and 1000 mcg vitamin B12. (NCT01704599)
Timeframe: Week 16 and Week 28

Number of Participants Within the Categories of Increasing and Decreasing Serum Homocysteine

Serum homocysteine measured at week 16 after 16 weeks of adalimumab and week 28 after 16 weeks of adalimumaband then 12 weeks of adalimumab plus 5 mg folic acid, 100mg B6 and 1000 mcg of B12 in adults ages 18-65 with moderate to sever plaque psoriasis.. (NCT01704599)
Timeframe: Week 16 and Week 28

Number of Participants Within the Categories of Increasing and Decreasing Serum Magnesium

Serum magnesium (Mg) was to be measured at baseline, Week 16 (on adalimumab) and at week 28 (on adalimumab plus folic acid, vitamins B6 and B12) in adult participants age 18 or older with moderate to severe plaque psoriasis. (NCT01704599)
Timeframe: Weeks 16 and 28

Number of Participants Within the Categories of Increasing and Decreasing Serum Phosphorus

Serum phosphorus (P) levels were to be measured weeks16 and 28 in adult participants age 18 and older with moderate to severe plaque psoriasis at week 0 on no systemic psoriasis medication; week 16 after 16 weeks of adalimumab and at week 28 after 16 weeks of adalimumab plus 12 weeks of adalimumab plus 5 mg folic acid, 100 mg vitamin B6 and 1000 mcg of B12. (NCT01704599)
Timeframe: Week 16 then Week 28

Number of Participants Within the Categories of Increasing and Decreasing Serum Vitamin B6 Level

Serum vitamin B6 levels were to be measured weeks16 after 16 weeks adalimumab and at week 28 after 16 weeks adalimumab and 12 weeks on adalimuamb, folic acid 5 mg, b6 100 mg and B12 1000 mcg in adult participants with moderate to sever plque psoriasis. (NCT01704599)
Timeframe: At Week 16 and Week 28

Number of Participants Within the Categories of Positive Urine Pregnancy Test (Urine Hcg)

Women of childbearing years over age 18 with moderate to severe plaque psoriasis on no systemic therapy at week 0 of study. (NCT01704599)
Timeframe: At screening

Number of Particpants With a Categorical PASI (Psoriasis Area and Severity Index) Change

PASI: formula based on body surface areas on head/neck, trunk, both arms & legs with disease quality grading induration, scale and erythema on participants ages 18-65 with moderate to severe plaque psoriasis measured at weeks 16 and 28. (NCT01704599)
Timeframe: Weeks 16 and 28

PASI Change in Participants With Baseline VEGF Above 140 pg/ml and in Participants With Normal Baseline VEGF

Baseline VEGF level at week zero related to PASI change Week 16 on adalimumab compared to Week 28 after additonal 12 weeks of adalimumab plus folic acid, vitamin B6 and B12 in adult psoriasis patients ages 18-65 with moderate to severe plaque psoriasis.High levels were greater than or equal to 140 pg/ml. Normal VEGF was below this level. (NCT01704599)
Timeframe: Week 16 and Week 28

PASI Change Related to Baseline Body Mass Index Above, Below and Equal to 27.3

Change in PASI from Week 16 on adalimumab to Week 28 on adalimumab, folic acid, vitamin B6 and B12 in adults ages 18-65 with moderate to severe plaque psoriasis. (NCT01704599)
Timeframe: Week 16 and Week 28

Psoriasis Change in Participants With High H. Pylori Titers and With Normal Titers.

Change in PASI from Week 16 after 16 weeks of adalimumab to Week 28 after another 12 weeks of adalimumab plus folic acid, vitamins B6 and B12 and Change reported by telephone 70 days after week 28 (NCT01704599)
Timeframe: Week 16 to Week 28 and Week 28 to post study day 70

Trials

3 trials available for pyridoxine and Apoplexy

Other Studies

7 other studies available for pyridoxine and Apoplexy